NASDAQ: PRLDPrelude Therapeutics Inc Stock Ownership - Who owns Prelude Therapeutics?
Insider buying vs selling
Have Prelude Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| David P. Bonita | Director | 2026-04-21 | 1,689,189 | $4.44 | $7.50MBuy |
| David P. Bonita | Director | 2026-04-21 | 1,126,126 | $4.44 | $5.00MBuy |
| Orbimed Advisors LLC | Director | 2026-04-21 | 1,689,189 | $4.44 | $7.50MBuy |
| Orbimed Advisors LLC | Director | 2026-04-21 | 1,126,126 | $4.44 | $5.00MBuy |
| Jane Huang | President CMO | 2025-10-04 | 3,355 | $1.47 | $4.93kSell |
PRLD insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when PRLD insiders and whales buy or sell their stock.
PRLD Shareholders
What type of owners hold Prelude Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Orbimed Advisors LLC | 12.25% | 9,776,491 | $44.87M | Insider |
| David P. Bonita | 12.25% | 9,776,491 | $44.87M | Insider |
| Baker Bros Advisors LP | 11.59% | 9,252,951 | $42.47M | Insider |
| Ra Capital Management LP | 9.88% | 7,882,882 | $36.18M | Insider |
| Krishna Vaddi | 3.38% | 2,693,625 | $12.36M | Insider |
| Paul A. Friedman | 0.63% | 500,098 | $2.30M | Insider |
| Andrew Combs | 0.60% | 480,123 | $2.20M | Insider |
| Peggy Scherle | 0.22% | 172,920 | $793.70k | Insider |
| Sean P. Brusky | 0.13% | 100,000 | $459.00k | Insider |
| Jane Huang | 0.11% | 86,917 | $398.95k | Insider |
PRLD vs Biotech Stocks
Prelude Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.